Difficulty: Medium
Average Score: 70%
Practice
A healthy 20-day-old male examination reveals a palpable liver margin below the right costal margin; lab findings: white blood count, 18700/mm3; hemoglobin, 8.8 g/dl; blast cells, 10%; the BEST approach for the management is consistent with acute myeloproliferative disorder
Correct answer
A
Rationale
The correct approach for the management of a healthy 20-day-old male with a palpable liver margin, elevated white blood count, low hemoglobin, and blast cells consistent with acute myeloproliferative disorder is intensive chemotherapy (Option A).
Intensive chemotherapy is the standard treatment for acute myeloproliferative disorders in children. It aims to reduce the blast cell population, restore normal blood cell production, and prevent disease progression.
Low dose chemotherapy pulses (Option B) may not be sufficient to adequately treat the aggressive nature of acute myeloproliferative disorders in pediatric patients. Bone marrow transplantation (Option C) is usually reserved for cases of refractory or relapsed disease, or when intensive chemotherapy fails.
Close follow-up (Option D) alone is not a sufficient treatment for acute myeloproliferative disorders, as prompt intervention with chemotherapy is necessary to improve outcomes in these cases.
In an educational context, understanding the appropriate treatment for pediatric hematologic disorders is crucial for healthcare providers working with children. Recognizing the need for intensive chemotherapy in this scenario highlights the importance of timely and effective management to improve patient outcomes and reduce the risk of disease progression.
Intensive chemotherapy is the standard treatment for acute myeloproliferative disorders in children. It aims to reduce the blast cell population, restore normal blood cell production, and prevent disease progression.
Low dose chemotherapy pulses (Option B) may not be sufficient to adequately treat the aggressive nature of acute myeloproliferative disorders in pediatric patients. Bone marrow transplantation (Option C) is usually reserved for cases of refractory or relapsed disease, or when intensive chemotherapy fails.
Close follow-up (Option D) alone is not a sufficient treatment for acute myeloproliferative disorders, as prompt intervention with chemotherapy is necessary to improve outcomes in these cases.
In an educational context, understanding the appropriate treatment for pediatric hematologic disorders is crucial for healthcare providers working with children. Recognizing the need for intensive chemotherapy in this scenario highlights the importance of timely and effective management to improve patient outcomes and reduce the risk of disease progression.